**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 65820

**Manuscript Type:** REVIEW

**Multiple roles of Smad4 in tumorigenesis, stem cells, drug resistance, and cancer therapy**

Dai CJ *et al*. Role of Smad4 in cancer

Chuan-Jing Dai, Yu-Ting Cao, Fang Huang, Yi-Gang Wang

**Chuan-Jing Dai, Yu-Ting Cao, Yi-Gang Wang,** College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China

**Fang Huang,** Department of Pathology, Zhejiang Provincial People’s Hospital of Hangzhou Medical University, Hangzhou 310014, Zhejiang Province, China

**Author contributions:** Dai CJ wrote the paper; Cao YT and Huang F wrote the partial manuscript, and contributed equally to this work; Wang YG designed the layout of the review and edited the manuscript.

**Supported by** the National Natural Science Foundation of China, No. 8180306; the Natural Science Foundation of Zhejiang Province, No. LY18C070002; and the 521 Talent Project of Zhejiang Sci-Tech University, No. 2021437620 and No. 2019337459.

**Corresponding author: Yi-Gang Wang, PhD, Professor,** College of Life Sciences and Medicine, Zhejiang Sci-Tech University, No. 2 Street of Xiasha District, Hangzhou 310018, Zhejiang Province, China. wangyigang43@163.com

**Received:** March 16, 2021

**Revised:** May 13, 2021

**Accepted: December 21, 2021**

**Published online:**

**Abstract**

The transforming growth factor (TGF)-β signaling pathway controls many cellular processes, including proliferation, differentiation, and apoptosis. Abnormalities in the TGF-β signaling pathway and its components are closely related to the occurrence of many human diseases, including cancer. Mothers against decapentaplegic homolog 4 (Smad4), also known as deleted in pancreatic cancer locus 4, is a typical tumor suppressor candidate gene locating at q21.1 of human chromosome 18 and the common mediator of the TGF-β/Smad and bone morphogenetic protein/Smad signaling pathways. It is believed that Smad4 inactivation correlates with the development of tumors and stem cell fate decisions. Smad4 also interacts with cytokines, miRNAs, and other signaling pathways, jointly regulating cell behavior. However, the regulatory function of Smad4 in tumorigenesis, stem cells, and drug resistance is currently controversial. In addition, Smad4 represents an attractive therapeutic target for cancer. Elucidating the specific role of Smad4 is important for understanding the mechanism of tumorigenesis and cancer treatment. Here, we review the identification and characterization of Smad4, the canonical TGF-β/Smad pathway, as well as the multiple roles of Smad4 in tumorigenesis, stem cells, and drug resistance. Furthermore, we provide novel insights into the prospects of Smad4-targeted cancer therapy and the challenges that it will face in the future.

**Key Words:** Cancer therapy; Drug resistance; Mothers against decapentaplegic homolog 4; Stemness; Transforming growth factor-β; Tumorigenesis

Dai CJ, Cao YT, Huang F, Wang YG. Multiple roles of Smad4 in tumorigenesis, stem cells, drug resistance, and cancer therapy. *World J Stem Cells* 2021; In press

**Core Tip:** Mothers against decapentaplegic homolog 4 (Smad4) is regarded as a tumor suppressor. Recent studies have shown that Smad4 plays a tumor-promoting role in specific types of cancer, rather than a tumor-suppressing role. Smad4 also correlates with the stem cells fate and drug resistance of cancer cells. Elucidating the specific role of Smad4 is of positive guiding significance for understanding the mechanism of tumorigenesis and cancer treatment. In this review, we focus on the multiple roles of Smad4 in tumorigenesis, stem cells, and drug resistance, and provide novel insights into the prospect of Smad4 in combination therapy.

**INTRODUCTION**

The transforming growth factor (TGF)-β signaling pathway controls several cell behaviors, including proliferation, inflammation, differentiation, and apoptosis[1,2]. Abnormalities of the TGF-β signaling pathway and its components are related to many human diseases such as fibrosis[3], immune diseases[4], and cancer[5]. Although TGF-β signals are mainly transmitted to the nucleus through the TGF-β/mothers against decapentaplegic homolog (Smad) signaling pathway[6], TGF-β superfamily ligands often interact with other signaling pathways, including JNK/p38, PI3K/AKT, ERK/MAPK, and integrin signaling pathways, regulating various cellular responses in a non-Smad-dependent manner[7-9]. The function of TGF-β in tumorigenesis is frequently described as a double-edged sword, but the precise mechanism for this phenomenon is still unclear[5,10,11]. In addition, TGF-β plays a role in the development of cardiac[12] and kidney[3] fibrosis and interacts with integrins to mediate asthmatic remodeling of the airway[13]. Moreover, TGF-β exerts an immunosuppressive function[14]. In recent years, studies on TGF-β have been focused on elucidating the regulation and effects of its upstream and downstream components on various diseases, as well as the interaction between different factors and TGF-β[10,15,16]. Understanding of these processes may improve the diagnosis and treatment of these diseases in the future.

Cancer has become a major threat to human health worldwide. In 2020 alone, 19.3 million new cases were diagnosed, and nearly 10 million people died of cancer[17]. Unfortunately, our current understanding of the mechanism of tumorigenesis is not enough to completely overcome cancer[18]. Smad4, a key component of the canonical TGF-β signaling pathway, exhibits varying degrees of inactivation among cancers[19], and its expression is significantly correlated with tumor development and prognosis in cancer patients[20,21]. Therefore, Smad4 is potently regarded as a tumor suppressor. Moreover, considering the critical role of Smad4 in tumor progression, Smad4 can be an attractive target for cancer treatment[22]. Additional novel options for cancer therapy were revealed by demonstrating that many RNAs directly/indirectly targeting Smad4, including miRNAs, circular (circ) RNAs, and long noncoding (lnc) RNAs, are dysregulated during cancer progression[23-25]. In the past decade, it has been found that Smad4 seems to play a tumor-promoting role in certain types of cancer, such as hepatocellular carcinoma[26,27]. In addition, an increasing number of studies demonstrated a close association of Smad4 with stem cell fate[28] and drug resistance of cancer cells[29]. Elucidating the specific role of Smad4 is important for understanding the mechanism of tumorigenesis and cancer treatment. Here, we review the identification and characteristics of Smad4, and the canonical TGF-β signaling pathway, and summarize the multiple regulatory functions of Smad4 in tumorigenesis, stem cell fate, and drug resistance. In addition, we provide new insights into the prospects of Smad4-targeting cancer therapy and its challenges in the future.

**IDENTIFICATION AND CHARACTERISTICS OF SMAD4**

*Smad4*, also known as deleted in pancreatic cancer locus 4 (*DPC4*), was initially found as a tumor suppressor candidate gene in human pancreatic carcinoma in 1996[30]. The term “Smad” was a combination of the *sma* gene of *Caenorhabditis elegans* and the *mad* gene of *Drosophila melanogaster*[31]. Subsequently, Smad4 mutations were found in additional types of tumors, such as gastrointestinal carcinoid[32], prostate cancer[33], squamous cell carcinoma[34], and lung cancer[35]. The gene coding for Smad4 is located at human chromosome locus 18q21.1 (Figure 1A) and is composed of 12 exons and 10 introns[36]. The 12th exon was named exon 0 because it was discovered after the identification of 11 exons and is located upstream of exon 1[32].

Smad4 protein consists of 552 amino acids and has a molecular weight of 60 kDa[36]. It is composed of the N-terminal mad homology domain 1 (MH1), the middle linker region including nuclear export signal and Smad activation domain (SAD), as well as the C-terminal MH2[37]. The MH1 domain of Smad4 is involved in DNA binding by recognizing the Smad-binding site of DNA. The SAD of the linker region and MH2 domain are responsible for transcriptional activity. Additionally, the MH2 domain interacts with the MH1 domain of other Smads, enabling the transduction of various signaling pathways, including the TGF-β signaling (Figure 1B).

**TGF-**β**/SMAD AND BMP/SMAD SIGNALING PATHWAYS**

The canonical TGF-β signaling pathway is an uncomplicated linear cascade, which involves TGF-β superfamily ligands, receptors, and signal transducers (Figure 2)[38]. At present, there are 33 known TGF-β ligands encoded by mammalian genomes, including activin, nodal, TGF-βs, bone morphogenetic proteins (BMPs), and growth differentiation factors (GDFs)[39,40]. According to the difference in structure and function, these polypeptides can be subdivided into two families: TGF-βs (TGF-β, GDF, nodal, and activin) and BMPs (BMP2, BMP4, and BMP7). The TGF-β type I and type II receptors (TβRI and TβRII) are composed of several pairs of serine/threonine protein kinases[41,42].

The eight known Smads are divided into three categories, including a common Smad (Co-Smad, Smad4), two inhibitory Smads (I-Smads, Smad6, and Smad7), and receptor-regulated Smads (R-Smads, Smad2/3 transducing TGF-β signaling, and Smad1/5/8 transducing BMP signaling). Co-Smad and Smad4/DPC4 bind to R-Smads, forming two different complexes, Smad4/Smad2/3 and Smad4/Smad1/5/8. Subsequently, the heteromeric complexes are translocated into the nucleus, where they interact with transcriptional factors and bind to regulatory elements of target genes, affecting their expression[43]. Smad6 and Smad7 can both inhibit the transcriptional activity of target genes, thus blocking TGF-β signal transmission. It must be emphasized that Smad6 acts in a manner that is not always consistent with that of Smad7[44,45].

**MULTIPLE ROLES OF SMAD4 IN TUMORIGENESIS**

Due to the multiple interactions of environmental chemicals, genes, and endogenous signals, the process of carcinogenesis is extremely complex[46]. As a tumor suppressor gene, *Smad4* exerts its inhibitory effect on tumor cells primarily *via* the canonical TGF-β signaling pathway[47,48]. The mechanism of this inhibition, which prevents carcinogenesis, involves the role of Smad4 in inhibiting the tumor-promoting activity of proinflammatory cytokines, inducing the cell cycle arrest, and promoting apoptosis through activating the TGF-β/BMP/Smad4 axis. However, once the *Smad4* gene is mutated, TGF-β cannot induce G1 or G2 cell cycle arrest and switch from tumor suppressor to tumor promoter, leading to tumor growth and metastasis[10,49]. In addition, Smad4 is indispensable for the tumor suppressor function of TGF-β[50]. So far, there are many contradictory results and conclusions about the role of Smad4 in tumorigenesis. Here, we focus on pancreatic cancer and hepatocellular carcinoma (HCC) to discuss the role of Smad4 in cancer progression (Figure 3).

It is recognized that Smad4 acts as a tumor suppressor in pancreatic cancer. *Smad4* mutation or deletion is found in > 50% of pancreatic cancer and is associated with the proliferation and metastasis of tumor cells[51,52]. The alterations in the *Smad4* gene mainly include deletion, frameshift mutation, point mutation, amplification, and translocation[19,22]. Furthermore, *Smad4* gene mutation is associated with stages of pancreatic cancer. A study by Notta *et al*[53] showed that the inactivation rate of Smad4 in mid-advanced pancreatic cancer was higher than it in early pancreatic cancer. Therefore, Smad4 dysfunction may be considered an advanced event in pancreatic cancer. Mechanically, the behavior that Smad4 deletion accelerates the progression of pancreatic cancer may be related to the increased expression of HNF4G, PAR-4, and PGK-1[51,54,55]. Additionally, Smad4 mutation in mice does not directly contribute to the formation of pancreatic tumors[56], indicating that a single Smad4 mutation is not sufficient to initiate pancreatic carcinogenesis. Thus, mutations in *Smad4* are likely to cooperate with mutations in other genes in promoting pancreatic cancer progression. For example, Izeradjene *et al*[57] revealed that the formation of mucinous cystic neoplasms is induced by synergistic effects of Kras-G12D and Smad4 mutations. The role of Smad4 in other human cancers, such as colorectal cancer (CRC)[58], gastric cancer[59], ovarian cancer[60] and head and neck squamous cell carcinoma (HNSCC)[61], is similar to that in pancreatic cancer. Downregulation of Smad4 is considered an early event of HNSCC, which is different from pancreatic cancer.

An interesting fact regarding HCC is that the role of Smad4 in HCC differs significantly from that in cancers mentioned above. The nuclear level of Smad4 in liver cancer tissue is markedly higher than that in the adjacent noncancerous tissue[26]. The ability of liver cancer cells to form colonies and migrate was significantly reduced after *Smad4* gene knockout in mouse models. Yuan *et al*[62] showed that ubiquitin-specific proteases promote HCC cell migration and invasion by deubiquitinating and stabilizing Smad4 protein. These findings seem to indicate that Smad4 plays a tumor-promoting rather than tumor-suppressing role in HCC. However, the underlying mechanism of Smad4 in the pathogenesis of HCC remains elusive. We propose that this difference may be explained by the fact that the cellular behaviors of the TGF-β/Smad4 signaling pathway varies with types of cells, their extracellular matrix, TGF-β concentration, and tumor microenvironment. These possibilities warrant further investigation. It is certain that Smad4 plays multiple regulatory roles in carcinogenesis, and whether it has a tumor-promoting or tumor-suppressing function may depend on the microenvironment of tumor cells and surrounding stromal cells.

**SMAD4 IN STEM CELLS**

Besides tumorigenesis, Smad4 is involved in the self-renewal and pluripotency of human stem cells. It has been reported that several miRNAs targeting Smad4 negatively regulate the differentiation of human mesenchymal stem cells (hMSCs)[63,64], but the underlying mechanisms of stem cell differentiation are poorly understood. The Smad4/TAZ axis might be involved in this process. TAZ protein, a transcriptional coactivator with PDZ-binding motif, can bind to Smad4 protein and translocate to the nucleus, where it enhances the expression of osteogenic genes, promoting the osteogenic differentiation of hMSCs[65]. These findings suggest that Smad4 is essential for stem cell differentiation. However, Avery *et al*[28] demonstrated that human embryonic stem cells (hESCs) remain undifferentiated after *Smad4* gene knockdown, indicating that the single event of Smad4 inactivation does not induce stem cell differentiation. Similarly, Smad4 inactivation does not directly induce self-renewal of stem cells. For instance, Smad4 mutation has no effect on hESC self-renewal but is essential for their differentiation into cardiac mesodermal precursors[66].

BMP signaling is also indispensable for regulation of the proliferation of stem cells and maintenance of metabolic homeostasis[67]. BMP binds with leukemia inhibitory factor to maintain the self-renewal of ESCs[68]. Subsequent studies have documented that stem cell fate decisions induced by BMP may be related to Smad4. The BMP/Smad axis regulates the proliferation and differentiation of alveolar stem cells. BMP suppresses proliferation of alveolar type 2 epithelial cells (AT2s), while antagonists promoted the self-renewal of AT2s at the expense of differentiation[67]. BMP restricts the self-renewal of intestinal Lgr5+ stem cells by Smad4-mediated transcriptional repression and thus prevents excessive proliferation of epithelial cells[69]. Therefore, the inactivation of Smad4 may counteract the inhibitory effect of BMP on stem cell proliferation, contributing in this manner to the occurrence of cancer cells.

Cancer stem cells (CSCs) have many characteristics similar to stem cells. However, in contrast to stem cells, they exhibit tumorigenicity and invasiveness[70]. The gradual accumulation of genetic mutations in stem cells during the life of the organism is associated with the development of cancer[71], and results in tumor heterogeneity[72]. Therefore, elucidating the relationship between Smad4 and CSC fate may provide a clinical diagnostic index or potential therapeutic target for cancer. Xia *et al*[73] found that cyclin D1 interacts with Smad2/3 and Smad4, activating the cyclin D1/Smad pathway and upregulating the expression of stemness genes in liver CSCs. This result implies that the use of Smad inhibitors may be an effective strategy for targeting liver CSCs. Wen *et al*[74] showed that blocking the TGF-β/Smad/EMT pathway inhibited the self-renewal and metastasis of ovarian CSCs. In another study[75], Smad4 mutation was introduced into organoids derived from intestinal epithelium through the CRISPR-Cas9 system. Upon injection of these organoids into the spleen of mice, they formed micrometastases containing invading tumor cells, but they could not colonize the liver, suggesting that Smad4 mutation must be combined with additional factors to promote tumor invasion.

**SMAD4 IN DRUG RESISTANCE**

Drug resistance is the main cause of chemotherapy failure and tumor recurrence in cancer patients[76]. Drug resistance has been shown to be related to the activation of autophagy[77], a highly conserved catabolic process in which large cellular structures are degraded. Autophagy contributes to cell survival by recycling constituents of cellular structures[78]. Activation of autophagy not only mediates the resistance to chemotherapy but also induces autophagy-mediated cell death, which helps to eliminate tumor cells[52,79]. For instance, autophagy protects breast cancer cells from epirubicin-induced apoptosis and promotes the development of epirubicin resistance[80]. Peptidylarginine deiminase IV, a protein involved in many pathological processes, induces the resistance of HCC to chemotherapy by activating autophagy[81]. Autophagy may promote the development of multidrug resistance. Fortunately, inducing autophagy-mediated cell death can help overcome the resistance to chemotherapy, and there are many clinically available drugs that can regulate autophagy, such as chloroquine or hydroxychloroquine[82]. These autophagy regulators inhibit autophagy mainly by reducing autolysosome fusion[83]. In addition, TGF-β activates autophagy activation by both Smad and non-Smad pathways, promoting the survival of cancer cells[84,85]. Thus, Smad4 plays an indispensable role in TGF-β-induced autophagy and drug resistance (Figure 4).

Smad4 inactivation not only involves the development of drug resistance in cancer but also contributes to the crosstalk between TGF-β and other signaling pathways, accelerating this process. Zhang *et al*[86] demonstrated that Smad4 deletion induces the resistance of colon cancer cells to 5-fluorouracil (5-FU)-based therapy by activating the AKT pathway. Moreover, Smad4 deficiency inhibits 5-FU-mediated apoptosis[87]. Besides, the inactivation of Smad4 makes tumors resistant to other chemotherapeutic drugs. Smad4 mutation contributes to platinum resistance in non-small cell lung carcinoma[35] and to cetuximab resistance in HNSCC[29]. Targeting the rapamycin-insensitive companion of mTOR, a component of mammalian target of rapamycin complex 2, increases the sensitivity of Smad4-negative colon cancer to irinotecan[88]. Recent studies have demonstrated that Smad4 deficiency correlates with the development of resistance to chemotherapy and radiotherapy[89]. Therefore, Smad4 modifications may be a critical marker predicting the resistance of tumor cells to chemoradiation therapy[90]. In our view, elucidating the specific role of Smad4 in resistance of tumors to drugs and developing rational therapeutic applications of autophagy will help to improve the outcomes of treatment of drug-resistant tumors.

**SMAD4 IN CANCER THERAPY**

Given the key role of Smad4 in tumorigenesis, Smad4 is expected to be an attractive therapeutic target for tumors resistant to radiotherapy and chemotherapy. Many miRNAs, such as miR-224[91], miR-34a[92], and miR-205[93], are essential regulators of TGF-β-induced tumor suppression by affecting the TGF-β/Smad signaling pathway. Therefore, Smad4-targeting miRNAs may become novel therapeutic agents for cancer treatment. Other RNAs, including circRNAs[94] and lncRNAs[95], regulate the level of Smad4 protein by targeting Smad4-targeting miRNAs directly or indirectly. Proteins, such as ALK[96] and tripartite motif 47[97] that promote, respectively, Smad4 phosphorylation and ubiquitination, diminish the tumor suppressor effect of Smad4, indicating that suppressor molecules or enzymes that inhibit Smad4 activity may be a new option for the treatment of Smad4-negative cancers.

Many inhibitors targeting the TGF-β signaling pathway are being developed clinically[98]. Molecules such as TGF-β antibodies, antisense oligonucleotides, and small molecule inhibitors of TGF-β receptor kinase activity show immense clinical potential[99]. Although inhibition of the TGF-β signaling pathway is one of the strategies for cancer treatment, the clinical outcomes of targeting TGF-β signaling and its superfamily members are not satisfactory, suggesting that single target-based therapies are not sufficient to inhibit tumors[10].

Combination therapy is an increasingly important part of anticancer therapies, and has more advantages than single-drug therapy[100-102]. The combination of Smad4 targeting and traditional/nontraditional therapies may become a novel choice for anticancer treatment. Mariathasan *et al*[103] showed that the combined application of TGF-β inhibitors together with anti-PD-L1 antibodies decreased the TGF-β level and promoted the infiltration of T-cells into tumor cells, thereby enhancing antitumor immune response and leading to tumor apoptosis. Kassardjian and Wang[104] found that Smad4-positive tumors had a better response to neoadjuvant therapy, and the lymph node metastasis rate of Smad4-positive tumors was significantly lower, suggesting that Smad4 plays an important role in neoadjuvant therapy. In our previous research[105], we combined oncolytic virus therapy and targeted gene therapy to design a new oncolytic adenovirus CD55-Smad4, which can stably produce Smad4 protein *in vitro* and *in vivo*. CD55-Smad4 significantly inhibited proliferation, metastasis, and stemness of CRC cells. All these show that the combination therapy targeting Smad4 has clinical potential. Therefore, we believe that combination of Smad4-targeted therapy with traditional therapies of surgery, radiotherapy, and chemotherapy, and with emerging treatments such as PD-LI inhibitors, chimeric antigen receptor cell therapy, as well as our targeting gene virotherapy will significantly improve the outcomes of anticancer therapies.

**CONCLUSION**

Targeting abnormal signal transduction or abnormal metabolic pathway has always been the focus of anticancer research. *Smad4* gene mutations and its abnormal expression have been confirmed to dysregulate the TGF-β signaling pathway, transforming its function from a tumor suppressor to a tumor promoter[106]. This signaling disorder accelerates tumor progression, but the precise mechanism by which Smad4 affects tumor development remains unclear. An increasing number of studies have shown that targeting oncogenic miRNAs, circRNAs, and other RNAs can inhibit TGF-β-induced tumorigenesis by directly or indirectly acting on Smad4, increasing susceptibility of tumors to chemoradiation and improving the survival rate of cancer patients. Although the possibility of regulating tumor progression by these RNAs shows clinical potential, the underlying mechanisms are poorly understood.

Fortunately, the vigorous development of genome editing technologies such as CRISPR-Cas9 systems and AAV gene vectors has enabled the transformation of Smad4-targeted therapies into clinical reality[107,108]. Furthermore, it is asserted that the presence of Smad4 protein promotes the cell-to-cell spread of the vaccinia virus, which enables combining *Smad4* gene therapy with oncolytic virus therapy to effectively eliminate tumors[109]. In summary, although the specific mechanisms by which Smad4 affects carcinogenesis, metastasis, drug resistance, and other malignant features of tumors have not been completely clarified, Smad4-targeted therapies coupled with traditional therapies and emerging anticancer treatments have achieved good antitumor effects in animal models. Smad4 combination therapy shows potential for future clinical applications.

**REFERENCES**

1 **Blank U**, Karlsson S. TGF-β signaling in the control of hematopoietic stem cells. *Blood* 2015; **125**: 3542-3550 [PMID: 25833962 DOI: 10.1182/blood-2014-12-618090]

2 **Haque S**, Morris JC. Transforming growth factor-β: A therapeutic target for cancer. *Hum Vaccin Immunother* 2017; **13**: 1741-1750 [PMID: 28575585 DOI: 10.1080/21645515.2017.1327107]

3 **Meng XM**, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. *Nat Rev Nephrol* 2016; **12**: 325-338 [PMID: 27108839 DOI: 10.1038/nrneph.2016.48]

4 **Batlle E**, Massagué J. Transforming Growth Factor-β Signaling in Immunity and Cancer. *Immunity* 2019; **50**: 924-940 [PMID: 30995507 DOI: 10.1016/j.immuni.2019.03.024]

5 **Derynck R**, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. *Nat Genet* 2001; **29**: 117-129 [PMID: 11586292 DOI: 10.1038/ng1001-117]

6 **Tzavlaki K**, Moustakas A. TGF-β Signaling. *Biomolecules* 2020; **10** [PMID: 32210029 DOI: 10.3390/biom10030487]

7 **Luo K**. Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways. *Cold Spring Harb Perspect Biol* 2017; **9** [PMID: 27836834 DOI: 10.1101/cshperspect.a022137]

8 **Guo X**, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. *Cell Res* 2009; **19**: 71-88 [PMID: 19002158 DOI: 10.1038/cr.2008.302]

9 **Jahan N**, Hannila SS. Transforming growth factor β-induced expression of chondroitin sulfate proteoglycans is mediated through non-Smad signaling pathways. *Exp Neurol* 2015; **263**: 372-384 [PMID: 25446723 DOI: 10.1016/j.expneurol.2014.10.023]

10 **Colak S**, Ten Dijke P. Targeting TGF-β Signaling in Cancer. *Trends Cancer* 2017; **3**: 56-71 [PMID: 28718426 DOI: 10.1016/j.trecan.2016.11.008]

11 **Wang Y**, Xue Q, Zheng Q, Jin Y, Shen X, Yang M, Zhou X, Li Y. SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer. *Lab Invest* 2021; **101**: 463-476 [PMID: 33303972 DOI: 10.1038/s41374-020-00517-x]

12 **Khalil H**, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, Vagnozzi RJ, Liu R, Huynh T, Lee SJ, Karch J, Molkentin JD. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. *J Clin Invest* 2017; **127**: 3770-3783 [PMID: 28891814 DOI: 10.1172/JCI94753]

13 **Tatler AL**, John AE, Jolly L, Habgood A, Porte J, Brightling C, Knox AJ, Pang L, Sheppard D, Huang X, Jenkins G. Integrin αvβ5-mediated TGF-β activation by airway smooth muscle cells in asthma. *J Immunol* 2011; **187**: 6094-6107 [PMID: 22025551 DOI: 10.4049/jimmunol.1003507]

14 **Travis MA**, Sheppard D. TGF-β activation and function in immunity. *Annu Rev Immunol* 2014; **32**: 51-82 [PMID: 24313777 DOI: 10.1146/annurev-immunol-032713-120257]

15 **Caja L**, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G, Fabregat I. TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer. *Int J Mol Sci* 2018; **19** [PMID: 29701666 DOI: 10.3390/ijms19051294]

16 **Derynck R**, Budi EH. Specificity, versatility, and control of TGF-β family signaling. *Sci Signal* 2019; **12** [PMID: 30808818 DOI: 10.1126/scisignal.aav5183]

17 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

18 **Qiu L**, Hu X, Jing Q, Zeng X, Chan KM, Han J. Mechanism of cancer: Oncohistones in action. *J Genet Genomics* 2018; **45**: 227-236 [PMID: 29804713 DOI: 10.1016/j.jgg.2018.04.004]

19 **Cicenas J**, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. *Cancers (Basel)* 2017; **9** [PMID: 28452926 DOI: 10.3390/cancers9050042]

20 **Ahmed S**, Bradshaw AD, Gera S, Dewan MZ, Xu R. The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance. *J Clin Med* 2017; **6** [PMID: 28067794 DOI: 10.3390/jcm6010005]

21 **Rosic J**, Dragicevic S, Miladinov M, Despotovic J, Bogdanovic A, Krivokapic Z, Nikolic A. SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response. *Exp Mol Pathol* 2021; **123**: 104714 [PMID: 34717960 DOI: 10.1016/j.yexmp.2021.104714]

22 **Qian Y**, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, Liu C. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. *J Hematol Oncol* 2020; **13**: 130 [PMID: 33008426 DOI: 10.1186/s13045-020-00958-3]

23 **Yan W**, Liu Z, Yang W, Wu G. miRNA expression profiles in Smad4-positive and Smad4-negative SW620 human colon cancer cells detected by next-generation small RNA sequencing. *Cancer Manag Res* 2018; **10**: 5479-5490 [PMID: 30519096 DOI: 10.2147/CMAR.S178261]

24 **Ma C**, Wang X, Yang F, Zang Y, Liu J, Wang X, Xu X, Li W, Jia J, Liu Z. Circular RNA hsa\_circ\_0004872 inhibits gastric cancer progression *via* the miR-224/Smad4/ADAR1 successive regulatory circuit. *Mol Cancer* 2020; **19**: 157 [PMID: 33172486 DOI: 10.1186/s12943-020-01268-5]

25 **Zhang C**, Hao Y, Wang Y, Xu J, Teng Y, Yang X. TGF-β/SMAD4-Regulated LncRNA-LINP1 Inhibits Epithelial-Mesenchymal Transition in Lung Cancer. *Int J Biol Sci* 2018; **14**: 1715-1723 [PMID: 30416386 DOI: 10.7150/ijbs.27197]

26 **Hernanda PY**, Chen K, Das AM, Sideras K, Wang W, Li J, Cao W, Bots SJ, Kodach LL, de Man RA, Ijzermans JN, Janssen HL, Stubbs AP, Sprengers D, Bruno MJ, Metselaar HJ, ten Hagen TL, Kwekkeboom J, Peppelenbosch MP, Pan Q. SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. *Oncogene* 2015; **34**: 5055-5068 [PMID: 25531314 DOI: 10.1038/onc.2014.425]

27 **Hiwatashi K**, Ueno S, Sakoda M, Kubo F, Tateno T, Kurahara H, Mataki Y, Maemura K, Ishigami S, Shinchi H, Natsugoe S. Strong Smad4 expression correlates with poor prognosis after surgery in patients with hepatocellular carcinoma. *Ann Surg Oncol* 2009; **16**: 3176-3182 [PMID: 19626374 DOI: 10.1245/s10434-009-0614-2]

28 **Avery S**, Zafarana G, Gokhale PJ, Andrews PW. The role of SMAD4 in human embryonic stem cell self-renewal and stem cell fate. *Stem Cells* 2010; **28**: 863-873 [PMID: 20235236 DOI: 10.1002/stem.409]

29 **Ozawa H**, Ranaweera RS, Izumchenko E, Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A, Ravi R, Perez J, Le QT, Kong CS, Jordan RC, Wang H, Kang H, Quon H, Sidransky D, Chung CH. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. *Clin Cancer Res* 2017; **23**: 5162-5175 [PMID: 28522603 DOI: 10.1158/1078-0432.CCR-16-1686]

30 **Hahn SA**, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 1996; **271**: 350-353 [PMID: 8553070 DOI: 10.1126/science.271.5247.350]

31 **Derynck R**, Gelbart WM, Harland RM, Heldin CH, Kern SE, Massagué J, Melton DA, Mlodzik M, Padgett RW, Roberts AB, Smith J, Thomsen GH, Vogelstein B, Wang XF. Nomenclature: vertebrate mediators of TGFbeta family signals. *Cell* 1996; **87**: 173 [PMID: 8861901 DOI: 10.1016/s0092-8674(00)81335-5]

32 **Mamot C**, Mild G, Reuter J, Laffer U, Metzger U, Terracciano L, Boulay JL, Herrmann R, Rochlitz C. Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer. *Br J Cancer* 2003; **88**: 420-423 [PMID: 12569386 DOI: 10.1038/sj.bjc.6600733]

33 **Horvath LG**, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. *Prostate* 2004; **59**: 234-242 [PMID: 15042598 DOI: 10.1002/pros.10361]

34 **Hernandez AL**, Young CD, Wang JH, Wang XJ. Lessons learned from SMAD4 Loss in squamous cell carcinomas. *Mol Carcinog* 2019; **58**: 1648-1655 [PMID: 31140647 DOI: 10.1002/mc.23049]

35 **Tan X**, Tong L, Li L, Xu J, Xie S, Ji L, Fu J, Liu Q, Shen S, Liu Y, Xiao Y, Gao F, Moses RE, Bardeesy N, Wang Y, Zhang J, Tang L, Li L, Wong K-K, Song D, Yang X, Liu J, Li X. Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation. *Nat Commun* 2021; **12**(1): 4853 [PMID: 34381046 DOI: 10.1038/s41467-021-24898-9]

36 **Shi Y**, Hata A, Lo RS, Massagué J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. *Nature* 1997; **388**: 87-93 [PMID: 9214508 DOI: 10.1038/40431]

37 **Zhao M**, Mishra L, Deng CX. The role of TGF-β/SMAD4 signaling in cancer. *Int J Biol Sci* 2018; **14**: 111-123 [PMID: 29483830 DOI: 10.7150/ijbs.23230]

38 **Budi EH**, Duan D, Derynck R. Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility. *Trends Cell Biol* 2017; **27**: 658-672 [PMID: 28552280 DOI: 10.1016/j.tcb.2017.04.005]

39 **Morikawa M**, Derynck R, Miyazono K. TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. *Cold Spring Harb Perspect Biol* 2016; **8** [PMID: 27141051 DOI: 10.1101/cshperspect.a021873]

40 **Weiss A**, Attisano L. The TGFbeta superfamily signaling pathway. *Wiley Interdiscip Rev Dev Biol* 2013; **2**: 47-63 [PMID: 23799630 DOI: 10.1002/wdev.86]

41 **David CJ**, Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer. *Nat Rev Mol Cell Biol* 2018; **19**: 419-435 [PMID: 29643418 DOI: 10.1038/s41580-018-0007-0]

42 **Vander Ark A**, Cao J, Li X. TGF-β receptors: In and beyond TGF-β signaling. *Cell Signal* 2018; **52**: 112-120 [PMID: 30184463 DOI: 10.1016/j.cellsig.2018.09.002]

43 **Massagué J**, Seoane J, Wotton D. Smad transcription factors. *Genes Dev* 2005; **19**: 2783-2810 [PMID: 16322555 DOI: 10.1101/gad.1350705]

44 **Hata A**, Lagna G, Massagué J, Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. *Genes Dev* 1998; **12**: 186-197 [PMID: 9436979 DOI: 10.1101/gad.12.2.186]

45 **Kavsak P**, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. *Mol Cell* 2000; **6**: 1365-1375 [PMID: 11163210 DOI: 10.1016/s1097-2765(00)00134-9]

46 **Peters JM**, Gonzalez FJ. The Evolution of Carcinogenesis. *Toxicol Sci* 2018; **165**: 272-276 [PMID: 30629266 DOI: 10.1093/toxsci/kfy184]

47 **Levy L**, Hill CS. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. *Mol Cell Biol* 2005; **25**: 8108-8125 [PMID: 16135802 DOI: 10.1128/MCB.25.18.8108-8125.2005]

48 **Ke Y**, Wang XJ. TGFβ Signaling in Photoaging and UV-Induced Skin Cancer. *J Invest Dermatol* 2021; **141**: 1104-1110 [PMID: 33358021 DOI: 10.1016/j.jid.2020.11.007]

49 **Hao Y**, Baker D, Ten Dijke P. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. *Int J Mol Sci* 2019; **20** [PMID: 31195692 DOI: 10.3390/ijms20112767]

50 **Li X**, Li J, Cai Y, Peng S, Wang J, Xiao Z, Wang Y, Tao Y, Li J, Leng Q, Wu D, Yang S, Ji Z, Han Y, Li L, Gao X, Zeng C, Wen X. Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. *Cancer Lett* 2018; **418**: 211-220 [PMID: 29331421 DOI: 10.1016/j.canlet.2018.01.031]

51 **Liang C**, Shi S, Qin Y, Meng Q, Hua J, Hu Q, Ji S, Zhang B, Xu J, Yu XJ. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. *Gut* 2020; **69**: 888-900 [PMID: 31611300 DOI: 10.1136/gutjnl-2018-317163]

52 **Fei N**, Wen S, Ramanathan R, Hogg ME, Zureikat AH, Lotze MT, Bahary N, Singhi AD, Zeh HJ, Boone BA. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. *Clin Transl Sci* 2021; **14**: 1822-1829 [PMID: 34002944 DOI: 10.1111/cts.13029]

53 **Notta F**, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, Denroche RE, Liang SB, Brown AM, Kim JC, Wang T, Simpson JT, Beck T, Borgida A, Buchner N, Chadwick D, Hafezi-Bakhtiari S, Dick JE, Heisler L, Hollingsworth MA, Ibrahimov E, Jang GH, Johns J, Jorgensen LG, Law C, Ludkovski O, Lungu I, Ng K, Pasternack D, Petersen GM, Shlush LI, Timms L, Tsao MS, Wilson JM, Yung CK, Zogopoulos G, Bartlett JM, Alexandrov LB, Real FX, Cleary SP, Roehrl MH, McPherson JD, Stein LD, Hudson TJ, Campbell PJ, Gallinger S. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. *Nature* 2016; **538**: 378-382 [PMID: 27732578 DOI: 10.1038/nature19823]

54 **Wang C**, Zhang T, Liao Q, Dai M, Guo J, Yang X, Tan W, Lin D, Wu C, Zhao Y. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. *Protein Cell* 2021; **12**: 128-144 [PMID: 32737864 DOI: 10.1007/s13238-020-00760-4]

55 **Mohd Faheem M**, Rasool RU, Ahmad SM, Jamwal VL, Chakraborty S, Katoch A, Gandhi SG, Bhagat M, Goswami A. Par-4 mediated Smad4 induction in PDAC cells restores canonical TGF-β/ Smad4 axis driving the cells towards lethal EMT. *Eur J Cell Biol* 2020; **99**: 151076 [PMID: 32439219 DOI: 10.1016/j.ejcb.2020.151076]

56 **Colvin EK**, Scarlett CJ. A historical perspective of pancreatic cancer mouse models. *Semin Cell Dev Biol* 2014; **27**: 96-105 [PMID: 24685616 DOI: 10.1016/j.semcdb.2014.03.025]

57 **Izeradjene K**, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, Hingorani SR. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. *Cancer Cell* 2007; **11**: 229-243 [PMID: 17349581 DOI: 10.1016/j.ccr.2007.01.017]

58 **Ogawa R**, Yamamoto T, Hirai H, Hanada K, Kiyasu Y, Nishikawa G, Mizuno R, Inamoto S, Itatani Y, Sakai Y, Kawada K. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils *via* the CXCL1/8-CXCR2 Axis. *Clin Cancer Res* 2019; **25**: 2887-2899 [PMID: 30705034 DOI: 10.1158/1078-0432.CCR-18-3684]

59 **Leng A**, Liu T, He Y, Li Q, Zhang G. Smad4/Smad7 balance: a role of tumorigenesis in gastric cancer. *Exp Mol Pathol* 2009; **87**: 48-53 [PMID: 19341727 DOI: 10.1016/j.yexmp.2009.03.003]

60 **Wang J**, Li Y, Zhou JH, Shen FR, Shi X, Chen YG. CircATRNL1 activates Smad4 signaling to inhibit angiogenesis and ovarian cancer metastasis *via* miR-378. *Mol Oncol* 2021; **15**: 1217-1233 [PMID: 33372356 DOI: 10.1002/1878-0261.12893]

61 **Lin LH**, Chang KW, Cheng HW, Liu CJ. *SMAD4* Somatic Mutations in Head and Neck Carcinoma Are Associated With Tumor Progression. *Front Oncol* 2019; **9**: 1379 [PMID: 31867281 DOI: 10.3389/fonc.2019.01379]

62 **Yuan T**, Chen Z, Yan F, Qian M, Luo H, Ye S, Cao J, Ying M, Dai X, Gai R, Yang B, He Q, Zhu H. Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein. *Mol Oncol* 2020; **14**: 197-210 [PMID: 31721429 DOI: 10.1002/1878-0261.12596]

63 **Ma X**, Fan C, Wang Y, Du Y, Zhu Y, Liu H, Lv L, Liu Y, Zhou Y. MiR-137 knockdown promotes the osteogenic differentiation of human adipose-derived stem cells *via* the LSD1/BMP2/SMAD4 signaling network. *J Cell Physiol* 2020; **235**: 909-919 [PMID: 31241766 DOI: 10.1002/jcp.29006]

64 **Gu Z**, Long J, Li Y, Wang X, Wang H. MiR-125a-3p negatively regulates osteoblastic differentiation of human adipose derived mesenchymal stem cells by targeting Smad4 and Jak1. *Am J Transl Res* 2019; **11**: 2603-2615 [PMID: 31105866]

65 **Park JS**, Kim M, Song NJ, Kim JH, Seo D, Lee JH, Jung SM, Lee JY, Lee J, Lee YS, Park KW, Park SH. A Reciprocal Role of the Smad4-Taz Axis in Osteogenesis and Adipogenesis of Mesenchymal Stem Cells. *Stem Cells* 2019; **37**: 368-381 [PMID: 30444564 DOI: 10.1002/stem.2949]

66 **Xu J**, Gruber PJ, Chien KR. SMAD4 Is Essential for Human Cardiac Mesodermal Precursor Cell Formation. *Stem Cells* 2019; **37**: 216-225 [PMID: 30376214 DOI: 10.1002/stem.2943]

67 **Chung MI**, Bujnis M, Barkauskas CE, Kobayashi Y, Hogan BLM. Niche-mediated BMP/SMAD signaling regulates lung alveolar stem cell proliferation and differentiation. *Development* 2018; **145** [PMID: 29752282 DOI: 10.1242/dev.163014]

68 **Ying QL**, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. *Cell* 2003; **115**: 281-292 [PMID: 14636556 DOI: 10.1016/s0092-8674(03)00847-x]

69 **Qi Z**, Li Y, Zhao B, Xu C, Liu Y, Li H, Zhang B, Wang X, Yang X, Xie W, Li B, Han JJ, Chen YG. BMP restricts stemness of intestinal Lgr5+ stem cells by directly suppressing their signature genes. *Nat Commun* 2017; **8**: 13824 [PMID: 28059064 DOI: 10.1038/ncomms13824]

70 **Batlle E**, Clevers H. Cancer stem cells revisited. *Nat Med* 2017; **23**: 1124-1134 [PMID: 28985214 DOI: 10.1038/nm.4409]

71 **Vlashi E**, Pajonk F. Cancer stem cells, cancer cell plasticity and radiation therapy. *Semin Cancer Biol* 2015; **31**: 28-35 [PMID: 25025713 DOI: 10.1016/j.semcancer.2014.07.001]

72 **Prasetyanti PR**, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. *Mol Cancer* 2017; **16**: 41 [PMID: 28209166 DOI: 10.1186/s12943-017-0600-4]

73 **Xia W**, Lo CM, Poon RYC, Cheung TT, Chan ACY, Chen L, Yang S, Tsao GSW, Wang XQ. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells. *Oncotarget* 2017; **8**: 38811-38824 [PMID: 28415588 DOI: 10.18632/oncotarget.16402]

74 **Wen H**, Qian M, He J, Li M, Yu Q, Leng Z. Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-β pathway. *PLoS One* 2020; **15**: e0230230 [PMID: 32214328 DOI: 10.1371/journal.pone.0230230]

75 **Matano M**, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, Kanai T, Sato T. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. *Nat Med* 2015; **21**: 256-262 [PMID: 25706875 DOI: 10.1038/nm.3802]

76 **Assaraf YG**, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH. The multi-factorial nature of clinical multidrug resistance in cancer. *Drug Resist Updat* 2019; **46**: 100645 [PMID: 31585396 DOI: 10.1016/j.drup.2019.100645]

77 **Zamame Ramirez JA**, Romagnoli GG, Kaneno R. Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy. *Life Sci* 2021; **265**: 118745 [PMID: 33186569 DOI: 10.1016/j.lfs.2020.118745]

78 **Smith AG**, Macleod KF. Autophagy, cancer stem cells and drug resistance. *J Pathol* 2019; **247**: 708-718 [PMID: 30570140 DOI: 10.1002/path.5222]

79 **Su Z**, Yang Z, Xu Y, Chen Y, Yu Q. Apoptosis, autophagy, necroptosis, and cancer metastasis. *Mol Cancer* 2015; **14**: 48 [PMID: 25743109 DOI: 10.1186/s12943-015-0321-5]

80 **Sun WL**, Chen J, Wang YP, Zheng H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. *Autophagy* 2011; **7**: 1035-1044 [PMID: 21646864 DOI: 10.4161/auto.7.9.16521]

81 **Fan T**, Zhang C, Zong M, Zhao Q, Yang X, Hao C, Zhang H, Yu S, Guo J, Gong R, Fan S, Wei L, Fan L. Peptidylarginine deiminase IV promotes the development of chemoresistance through inducing autophagy in hepatocellular carcinoma. *Cell Biosci* 2014; **4**: 49 [PMID: 25922661 DOI: 10.1186/2045-3701-4-49]

82 **Amaravadi RK**, Kimmelman AC, Debnath J. Targeting Autophagy in Cancer: Recent Advances and Future Directions. *Cancer Discov* 2019; **9**: 1167-1181 [PMID: 31434711 DOI: 10.1158/2159-8290.CD-19-0292]

83 **Mauthe M**, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, Coppes RP, Engedal N, Mari M, Reggiori F. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. *Autophagy* 2018; **14**: 1435-1455 [PMID: 29940786 DOI: 10.1080/15548627.2018.1474314]

84 **Kiyono K**, Suzuki HI, Matsuyama H, Morishita Y, Komuro A, Kano MR, Sugimoto K, Miyazono K. Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells. *Cancer Res* 2009; **69**: 8844-8852 [PMID: 19903843 DOI: 10.1158/0008-5472.CAN-08-4401]

85 **Liang C**, Xu J, Meng Q, Zhang B, Liu J, Hua J, Zhang Y, Shi S, Yu X. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. *Autophagy* 2020; **16**: 486-500 [PMID: 31177911 DOI: 10.1080/15548627.2019.1628540]

86 **Zhang B**, Zhang B, Chen X, Bae S, Singh K, Washington MK, Datta PK. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. *Br J Cancer* 2014; **110**: 946-957 [PMID: 24384683 DOI: 10.1038/bjc.2013.789]

87 **Papageorgis P**, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, Zhou JR, Thiagalingam S. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. *Cancer Res* 2011; **71**: 998-1008 [PMID: 21245094 DOI: 10.1158/0008-5472.CAN-09-3269]

88 **Wong CK**, Lambert AW, Ozturk S, Papageorgis P, Lopez D, Shen N, Sen Z, Abdolmaleky HM, Győrffy B, Feng H, Thiagalingam S. Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. *Mol Cancer Res* 2020; **18**: 414-423 [PMID: 31932471 DOI: 10.1158/1541-7786.MCR-19-0525]

89 **Jiang D**, Wang X, Wang Y, Philips D, Meng W, Xiong M, Zhao J, Sun L, He D, Li K. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. *Virchows Arch* 2019; **475**: 39-47 [PMID: 31056731 DOI: 10.1007/s00428-019-02576-y]

90 **Ezrova Z**, Nahacka Z, Stursa J, Werner L, Vlcak E, Kralova Viziova P, Berridge MV, Sedlacek R, Zobalova R, Rohlena J, Boukalova S, Neuzil J. SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition *via* promotion of mitophagy. *Oncogene* 2021; **40**: 2539-2552 [PMID: 33686239 DOI: 10.1038/s41388-021-01726-4]

91 **Zhou J**, Hu M, Wang F, Song M, Huang Q, Ge B. miR-224 Controls Human Colorectal Cancer Cell Line HCT116 Proliferation by Targeting Smad4. *Int J Med Sci* 2017; **14**: 937-942 [PMID: 28924364 DOI: 10.7150/ijms.19565]

92 **Qi Y**, Zhao A, Yang P, Jin L, Hao C. miR-34a-5p Attenuates EMT through targeting SMAD4 in silica-induced pulmonary fibrosis. *J Cell Mol Med* 2020; **24**: 12219-12224 [PMID: 32929850 DOI: 10.1111/jcmm.15853]

93 **Chu P**, Liang A, Jiang A, Zong L. miR-205 regulates the proliferation and invasion of ovarian cancer cells *via* suppressing PTEN/SMAD4 expression. *Oncol Lett* 2018; **15**: 7571-7578 [PMID: 29725462 DOI: 10.3892/ol.2018.8313]

94 **Liu J**, Dai X, Guo X, Cheng A, Mac SM, Wang Z. Circ-OXCT1 Suppresses Gastric Cancer EMT and Metastasis by Attenuating TGF-β Pathway Through the Circ-OXCT1/miR-136/SMAD4 Axis. *Onco Targets Ther* 2020; **13**: 3987-3998 [PMID: 32523351 DOI: 10.2147/OTT.S239789]

95 **Xiao T**, Zou Z, Xue J, Syed BM, Sun J, Dai X, Shi M, Li J, Wei S, Tang H, Zhang A, Liu Q. LncRNA H19-mediated M2 polarization of macrophages promotes myofibroblast differentiation in pulmonary fibrosis induced by arsenic exposure. *Environ Pollut* 2021; **268**: 115810 [PMID: 33162208 DOI: 10.1016/j.envpol.2020.115810]

96 **Zhang Q**, Xiao M, Gu S, Xu Y, Liu T, Li H, Yu Y, Qin L, Zhu Y, Chen F, Wang Y, Ding C, Wu H, Ji H, Chen Z, Zu Y, Malkoski S, Li Y, Liang T, Ji J, Qin J, Xu P, Zhao B, Shen L, Lin X, Feng XH. ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions. *Nat Cell Biol* 2019; **21**: 179-189 [PMID: 30664791 DOI: 10.1038/s41556-018-0264-3]

97 **Liang Q**, Tang C, Tang M, Zhang Q, Gao Y, Ge Z. TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4. *J Exp Clin Cancer Res* 2019; **38**: 159 [PMID: 30979374 DOI: 10.1186/s13046-019-1143-x]

98 **Huynh LK**, Hipolito CJ, Ten Dijke P. A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment. *Biomolecules* 2019; **9** [PMID: 31744193 DOI: 10.3390/biom9110743]

99 **Syed V**. TGF-β Signaling in Cancer. *J Cell Biochem* 2016; **117**: 1279-1287 [PMID: 26774024 DOI: 10.1002/jcb.25496]

100 **Nastiuk KL**, Krolewski JJ. Opportunities and challenges in combination gene cancer therapy. *Adv Drug Deliv Rev* 2016; **98**: 35-40 [PMID: 26724249 DOI: 10.1016/j.addr.2015.12.005]

101 **Colli LM**, Machiela MJ, Zhang H, Myers TA, Jessop L, Delattre O, Yu K, Chanock SJ. Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. *Cancer Res* 2017; **77**: 3666-3671 [PMID: 28446466 DOI: 10.1158/0008-5472.CAN-16-3338]

102 **Martin NT**, Bell JC. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. *Mol Ther* 2018; **26**: 1414-1422 [PMID: 29703699 DOI: 10.1016/j.ymthe.2018.04.001]

103 **Mariathasan S**, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* 2018; **554**: 544-548 [PMID: 29443960 DOI: 10.1038/nature25501]

104 **Kassardjian A**, Wang HL. SMAD4-Expressing Pancreatic Ductal Adenocarcinomas Have Better Response to Neoadjuvant Therapy and Significantly Lower Lymph Node Metastasis Rates. *Pancreas* 2020; **49**: 1153-1160 [PMID: 32897998 DOI: 10.1097/MPA.0000000000001636]

105 **Xiao B**, Zhang L, Liu H, Fang H, Wang C, Huang B, Liu X, Zhou X, Wang Y. Oncolytic Adenovirus CD55-Smad4 Suppresses Cell Proliferation, Metastasis, and Tumor Stemness in Colorectal Cancer by Regulating Wnt/β-Catenin Signaling Pathway. *Biomedicines* 2020; **8** [PMID: 33322272 DOI: 10.3390/biomedicines8120593]

106 **Itatani Y**, Kawada K, Sakai Y. Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment. *Int J Mol Sci* 2019; **20** [PMID: 31756952 DOI: 10.3390/ijms20235822]

107 **Hudry E**, Vandenberghe LH. Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality. *Neuron* 2019; **101**: 839-862 [PMID: 30844402 DOI: 10.1016/j.neuron.2019.02.017]

108 **Maeder ML**, Gersbach CA. Genome-editing Technologies for Gene and Cell Therapy. *Mol Ther* 2016; **24**: 430-446 [PMID: 26755333 DOI: 10.1038/mt.2016.10]

109 **Gowripalan A**, Abbott CR, McKenzie C, Chan WS, Karupiah G, Levy L, Newsome TP. Cell-to-cell spread of vaccinia virus is promoted by TGF-β-independent Smad4 signalling. *Cell Microbiol* 2020; **22**: e13206 [PMID: 32237038 DOI: 10.1111/cmi.13206]

**Footnotes**

**Conflict-of-interest statement:** The authors do not have any possible conflicts of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 16, 2021

**First decision:** May 5, 2021

**Article in press:**

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Zhou P **S-Editor:** Wang JJ **L-Editor:** Wang TQ **P-Editor:**


**Figure Legends**




**Figure 1 Structure and features of Smad4.** A: Location of the *Smad4* gene. *Smad4* is located at q21.1 of human chromosome 18; B: Structural diagram of Smad4 protein. Smad4 protein consists of three domains: Mad homology domain 1 (MH1) at the N-terminal, MH2 at the C-terminal, and the linker region connecting MH1 and MH2. Functionally, MH1 is responsible for binding to the Smad-binding site, and MH2 is indispensable for transforming growth factor-β transcriptional activity. The middle linker is rich in regulatory sites controlling various signaling pathways and kinases and is essential for the regulation of transcriptional activity. MH1: Mad homology domain 1; MH2: Mad homology domain 2; NES: Nuclear export signal; SAD: Smad activation domain; Smad4: Mothers against decapentaplegic homolog 4.



**Figure 2** **Transforming growth factor-β/Smad4 and bone morphogenetic protein/mothers against decapentaplegic homolog signaling pathways.** Activated transforming growth factor-β (TGF-β) ligands or bone morphogenetic protein ligands bind to type II receptor (TβRII) on the cell membrane and recruit type I receptors (TβRI), forming receptor complexes (TβRI and TβRII).Phosphorylated receptor complexes phosphorylate Smad2/3 and Smad1/5/8 (R-Smads).Smad4 (Co-Smad) binds with R-Smads to form two different complexes (Smad4/Smad2/3 and Smad4/Smad1/5/8). The heteromeric complexes are translocated to the nucleus, where they regulate the expression of specific genes. Smad6 and Smad7 (I-Smads), which are typically located in the nucleus, can enter the cytoplasm upon activation and regulate the transcriptional activity of the TGF-β signaling pathway. Smad6 mainly competes with R-Smads for binding Smad4 to inhibit transcriptional activity, while Smad7 inhibits transcriptional activity mostly by preventing the phosphorylation of R-Smads. BMP: Bone morphogenetic protein; TFs: Transcription factors; Smad1-8: Mothers against decapentaplegic homolog 1-8; TGF-β: Transforming growth factor-β.



**Figure 3** **Different roles of Smad4 in the development of hepatocellular carcinoma and pancreatic cancer**. A: The role of Smad4 in liver carcinogenesis. During the development of hepatocellular carcinoma, the transcriptional activity of Smad4 is abnormally increased, and in combination with gene mutations, alcohol, pathogen infection, as well as other carcinogenic factors, contributes to the loss of cell cycle control, suppression of DNA damage repair, increased proliferation, and decreased apoptosis. These factors result in a higher metastatic ability of cancer cells and poor patient prognosis; B: The role of Smad4 in pancreatic carcinogenesis. During pancreatic cancer progression, the deletion or mutation of Smad4 leads to loss of Smad4 activity. The absence of Smad4 function, together with other carcinogenic factors such as gene mutations and pancreatic tissue injury, results in the loss of cell cycle control, suppression of DNA damage repair, increased proliferation, and decreased apoptosis. These factors result in a higher metastatic ability of cancer cells and poor patient prognosis. Smad4: Mothers against decapentaplegic homolog 4.



**Figure 4 Role of Smad4 in autophagy and drug resistance induced by transforming growth factor-β.** In cancer cells with decreased or absent expression of Smad4 (Smad4-negative cancer cells), Smad4 mutation combined with other autophagy inducing factors (autophagy inducers) activates autophagy *via* the transforming growth factor-β signaling pathway, so that cancer cells can obtain nutrition through autophagy, develop resistance to chemotherapy, and show enhanced proliferation, metastasis, and stemness. Smad4: Mothers against decapentaplegic homolog 4; TGF-β: Transforming growth factor-β.